Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy (Review)

被引:78
|
作者
Yuan, Jingsheng [1 ]
Yin, Zhijie [1 ]
Tao, Kaixiong [1 ]
Wang, Guobing [1 ]
Gao, Jinbo [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
insulin-like growth factor 1 receptor; cancer; chemotherapeutic resistance; mechanisms; review; FACTOR-I RECEPTOR; FACTOR-BINDING PROTEINS; REGULATES CISPLATIN RESISTANCE; PROTECTS TUMOR-CELLS; GENE-EXPRESSION; MULTIDRUG-RESISTANCE; SIGNALING PATHWAYS; TARGETING IGF1R; NUCLEAR TRANSLOCATION; TRANSCRIPTION FACTORS;
D O I
10.3892/ol.2017.7276
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Drug resistance is a primary cause of chemotherapeutic failure; however, how this resistance develops is complex. A comprehensive understanding of chemotherapeutic resistance mechanisms may aid in identifying more effective drugs and improve the survival rates of patients with cancer. Insulin-like growth factor 1 receptor (IGF1R), a member of the insulin receptor family, has been extensively assessed for biological activity, and its putative contribution to tumor cell development and progression. Furthermore, researchers have attended to drugs that target IGF1R since IGF1R functions as a membrane receptor. However, how IGF1R participates in chemotherapeutic resistance remains unclear. Therefore, the present study described the IGF1R gene and its associated signaling pathways, and offered details of IGF1R-induced tumor chemoresistance associated with promoting cell proliferation, inhibition of apoptosis, regulation of ATP-binding cassette transporter proteins and interactions with the extracellular matrix. The present study offered additional explanations for tumor chemotherapy resistance and provided a theoretical basis of IGF1R and its downstream pathways for future possible chemotherapy treatment options.
引用
收藏
页码:41 / 47
页数:7
相关论文
共 50 条
  • [1] The type 1 insulin-like growth factor receptor and resistance to DACH1
    DeAngelis, Tiziana
    Wu, Kongming
    Pestell, Richard
    Baserga, Renato
    CELL CYCLE, 2011, 10 (12) : 1956 - 1959
  • [2] Role of insulin-like growth factor 1 receptor signalling in cancer
    Larsson, O
    Girnita, A
    Girnita, L
    BRITISH JOURNAL OF CANCER, 2005, 92 (12) : 2097 - 2101
  • [3] Role of insulin-like growth factor 1 receptor signalling in cancer
    O Larsson
    A Girnita
    L Girnita
    British Journal of Cancer, 2005, 92 : 2097 - 2101
  • [4] Molecular imaging of insulin-like growth factor 1 receptor in cancer
    Zhang, Yin
    Cai, Weibo
    AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 2 (02): : 248 - 259
  • [5] Deciphering Brain Insulin Receptor and Insulin-Like Growth Factor 1 Receptor Signalling
    Kleinridders, A.
    JOURNAL OF NEUROENDOCRINOLOGY, 2016, 28 (11)
  • [6] Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy
    Hua, Hui
    Kong, Qingbin
    Yin, Jie
    Zhang, Jin
    Jiang, Yangfu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [7] Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved
    Hopkins, Alyse
    Crowe, Philip J.
    Yang, Jia-Lin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (05) : 639 - 650
  • [8] Regulation and function of insulin and insulin-like growth factor receptor signalling
    Choi, Eunhee
    Duan, Cunming
    Bai, Xiao-chen
    NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2025,
  • [9] Quantitative analysis of insulin-like growth factor 2 receptor and insulin-like growth factor binding proteins to identify control mechanisms for insulin-like growth factor 1 receptor phosphorylation
    Tian, Dan
    Mitchell, Isaiah
    Kreeger, Pamela K.
    BMC SYSTEMS BIOLOGY, 2016, 10
  • [10] Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy
    Tognon, Cristina E.
    Sorensen, Poul H. B.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (01) : 33 - 48